Waverley Pharma Inc experienced a significant drop in stock value, raising concerns among investors.
Waverley Pharma Inc (WAVE.V) faced a steep decline in its stock price yesterday, falling by 33.33%. This sharp drop has left investors questioning the stability of the biopharmaceutical company, which specializes in oncology therapeutics.
Advertisement
Waverley Pharma Inc
WAVE.V
WAVE.V
Waverley Pharma Inc
WealthAwesomeMarket cap
$540,000
P/E
0.0x
52W high
$0.03
52W low
$0.01
1W change
-33.33%
Beta
1.22
Analyst Price Targets
Based on analyst covering WAVE
Wall Street analysts forecast WAVE stock price to rise 99900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.00
+99900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on WAVE's historical volatility
30-Day Vol
514.9%
Annualized
90-Day Vol
511.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 โ C$0.06 |
| 60 trading days | C$0.01 | C$0.00 โ C$0.11 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of just CAD 540,000 and no profits to show, Waverley Pharma's recent performance highlights the inherent risks of investing in small-cap biotech firms.
Waverley Pharma's stock plummets by 33.33%
The stock closed at CA$0.01, reflecting a market cap of only CAD 540,000, indicating potential liquidity issues.
Bull case
Despite the recent downturn, Waverley Pharma has shown potential for growth. Last year, the company reported a remarkable 183.90% increase in revenue, which could attract future investment if they stabilize their operations.
Bear case
The significant drop in stock price raises concerns about the company's financial health. With a negative profit margin and no dividend yield, investing in Waverley Pharma carries risks that investors should consider carefully.
Market Reaction
Advertisement
The stock market reacted sharply to Waverley Pharma's performance, with a 33.33% decline indicating a loss of investor confidence. This downturn can be attributed to the company's precarious financial standing, as reflected in its low market cap and negative profit margins.
Company Overview
Founded in 2014 and headquartered in Winnipeg, Waverley Pharma focuses on developing oncology therapeutics. Despite reporting a significant revenue increase last year, the company's overall financial health remains a concern for investors, particularly given its recent stock performance. For more details, visit the Waverley Pharma stock page.
Future Outlook
Looking ahead, Waverley Pharma must address its financial challenges to regain investor trust. The recent CFO change could signal a shift in strategy, but without clear communication of a path forward, the company may continue to struggle in the competitive biopharmaceutical landscape. Investors should keep an eye on upcoming announcements and financial reports for signs of recovery.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
